Discovery Laboratories Inc. (DSCO)
-NasdaqCM | Prev Close: | 1.65 |
|---|
| Open: | N/A |
|---|
| Bid: | 1.61 x 1600 |
|---|
| Ask: | 1.74 x 2000 |
|---|
| 1y Target Est: | 7.00 |
|---|
| Beta: | 1.85 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 1.50 - 3.51 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 377,157 |
|---|
| Market Cap: | 72.21M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.92 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- SmithOnStocks Opines On Stocks: May 19th Editionat Seeking Alpha(Sun, May 19)
- Discovery Labs Announces Completion of $14.25 Million Public OfferingPR Newswire(Wed, May 15)
- DISCOVERY LABORATORIES INC /DE/ FinancialsEDGAR Online Financials(Sat, May 11)
- Discovery Labs to Float Stock Issueat Motley Fool(Fri, May 10)
- Discovery Labs Prices $14.25 Million Public Offering of Common StockPR Newswire(Fri, May 10)
- DISCOVERY LABORATORIES INC /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, FinanciEDGAR Online(Fri, May 10)
- Discovery Labs files to sell common stock, no amount giventheflyonthewall.com(Thu, May 9)
- Discovery Labs Announces Proposed Public Offering of Common StockPR Newswire(Thu, May 9)
- Discovery Labs Reports First Quarter 2013 Financial ResultsPR Newswire(Tue, May 7)
- DISCOVERY LABORATORIES INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, FinaEDGAR Online(Tue, May 7)
- Looking For Opportunity - 5 Biotechs That Crashedat Seeking Alpha(Mon, May 6)
- Discovery Labs Announces Recent AFECTAIR® PublicationsPR Newswire(Wed, May 1)
- The FDA Issues a Stunning Rejectionat Motley Fool(Mon, Apr 29)
- Discovery Laboratories Stumblesat Seeking Alpha(Tue, Apr 16)
- 3 Healthcare Stock Stories Not To Be Missedat Wall St. Cheat Sheet(Mon, Apr 15)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 270.45 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.94 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.28 |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Discovery Laboratories, Inc., a specialty biotechnology company, focuses on developing products for critical care patients with respiratory disease and care in pulmonary medicine.
View More